Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 88 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hyperpigmentation Clear all
Completed Not applicable Interventional

A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma

NCT02110134
View directory record Official record
Conditions
Melasma
Interventions
Revlite Laser System with hydroquinone skin care regimen, Hydroquinone skin care regimen
Device · Other
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 22, 2026, 2:11 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy

NCT00771355
View directory record Official record
Conditions
Vitiligo, Melasma, Hyperpigmentation, Hypopigmentation
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2011 · Synced Oct 22, 2026, 2:11 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Prevalence of Carbohydrate Intolerance in Lean and Obese Children

NCT00000112
View directory record Official record
Conditions
Obesity, Glucose Intolerance, Diabetes, Acanthosis Nigricans
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
8 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Phase 2 Interventional

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

NCT00375739
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Huntsville, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 22, 2026, 2:11 AM EDT
Completed No phase listed Observational

Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs

NCT06160167
View directory record Official record
Conditions
Multiple Myeloma
Interventions
IMiD treatment, No IMiD treatment, Systemic therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
4,204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An In Vivo Model for Postinflammatory Hyperpigmentation

NCT02905903
View directory record Official record
Conditions
Post-inflammatory Hyperpigmentation
Interventions
Tricholoacetic Acid (TCA)
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

TCA 15% Chemical Peel for Improvement in Hand Lentigines

NCT05471947
View directory record Official record
Conditions
Photoaging, Lentigo
Interventions
15% Trichloroacetic acid + 3% glycolic acid
Drug
Lead sponsor
Main Line Center for Laser Surgery
Other
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Straberi Epistamp Device for Postinflammatory Hyperpigmentation

NCT04740255
View directory record Official record
Conditions
Postinflammatory Hyperpigmentation
Interventions
Straberi Epistamp
Device
Lead sponsor
Universal Skincare Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma

NCT02977507
View directory record Official record
Conditions
Melasma
Interventions
Lytera 2.0, 4% Hydroquinone Topical Cream, SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen
Other · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 22, 2026, 2:11 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris

NCT03361345
View directory record Official record
Conditions
Postinflammatory Hyperpigmentation
Interventions
Tranexamic Acid, Vehicle
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color

NCT03402893
View directory record Official record
Conditions
Acne Vulgaris, Post Inflammatory Hyperpigmentation
Interventions
ONEXTON Topical Gel
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Children's Healthy Living Community Randomized Trial

NCT01881373
View directory record Official record
Conditions
Obesity, Acanthosis Nigricans, Central Obesity
Interventions
CHL program, Delayed Optimized CHL program
Other
Lead sponsor
University of Hawaii
Other
Eligibility
2 Years to 8 Years
Enrollment
9,840 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 22, 2026, 2:11 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma

NCT06415435
View directory record Official record
Conditions
Melasma
Interventions
Radiofrequency Microneedling
Device
Lead sponsor
Benev Company, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
La Jolla, California • Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 22, 2026, 2:11 AM EDT
Terminated Not applicable Interventional

Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma

NCT01745224
View directory record Official record
Conditions
Melasma
Interventions
Revlite Q switched Nd:YAG, Trivantage Q switched Nd: YAG
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 22, 2026, 2:11 AM EDT
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 22, 2026, 2:11 AM EDT
Withdrawn Phase 1 Interventional

Spironolactone for the Treatment of Melasma

NCT03953209
View directory record Official record
Conditions
Melasma
Interventions
Spironolactone 50Mg Tablet, Spironolactone 100Mg Tablet, Spironolactone 200Mg
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Not applicable Interventional

Study of Light Treatment and Laser Treatment for Melasma

NCT00509977
View directory record Official record
Conditions
Melasma
Interventions
Light Treatment, Laser Treatment
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Phase 2 Interventional Results available

Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma

NCT02730819
View directory record Official record
Conditions
Melasma
Interventions
Illuminate Cream
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 22, 2026, 2:11 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

LaseMD System for the Treatment of Melasma

NCT03456674
View directory record Official record
Conditions
Melasma
Interventions
LaseMD System
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 22, 2026, 2:11 AM EDT
Terminated Phase 4 Interventional Results available

Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma

NCT00669071
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%, Cetaphil® Moisturizing Cream as Inactive Control
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 74 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
La Jolla, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Not applicable Interventional

Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma

NCT02095756
View directory record Official record
Conditions
Melasma
Interventions
755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy), Lytera Skin Brightening System (Non-hydroquinone topical therapy)
Other
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 22, 2026, 2:11 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome

NCT00811590
View directory record Official record
Conditions
Peutz-Jeghers Syndrome
Interventions
Everolimus
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 2:11 AM EDT
Recruiting No phase listed Observational

Pancreas Registry and High Risk Registry

NCT02775461
View directory record Official record
Conditions
Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst, Family History of Pancreas Cancer, Genetic Mutations
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
1,368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2033
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 22, 2026, 2:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI

NCT05493280
View directory record Official record
Conditions
Hyperpigmentation
Interventions
MOXI
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 22, 2026, 2:11 AM EDT